title: Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
abstract: Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival benefits versus their comparators in randomized controlled trials, and other agents are showing promising results. A future in which metastatic castrate-resistant prostate cancer can be managed as a 'chronic disease' looks tantalizingly close. The challenge for clinicians will be to use these treatments rationally, in a way that optimizes each individual patient's chances of prolonged survival.
authors.affiliation: Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Fulwood, Preston, Lancashire, PR2 9HT, UK. alison.birtle@lthtr.nhs.uk
authors.forename: Alison
authors.initials: A
authors.lastname: Birtle
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000736:Androstenes; D000737:Androstenols; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; C552428:cabazitaxel; C089740:abiraterone